Temitayo Adebowale

Mr. Temitayo Adebowale


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
OOOmar Aaron Oudit
Omar Aaron Oudit
AAAbdulrahman Atasi
Abdulrahman Atasi
TATemitayo Adebowale
Temitayo Adebowale
KPKibwey Peterkin
Kibwey Peterkin
JPJamal Perry
Jamal Perry
JSJamil Shah
Jamil Shah
Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been studied by several groups and stratified into COX dependent and independent mechanisms. COX2 gene expression was significantly increased in colorectal cancer and various other gastrointestinal malignancies; pancreatic, esophageal and gastric cancer. Our study investigates the relationship of aspirin use and outcomes in patients with non metastatic pancreatic cancer. Methodology The Nationwide Inpatient Sample, NIS, database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for non metastatic pancreatic cancer and its decompensations using ICD-10 diagnostic codes. These patients were partitioned based on their use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of. Multivariate logistic regression was applied to the outcomes, and the Charlson Comorbidity Index was used to adjust for confounders. A p-value (pv) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 139,579 patients were identified with non-metastatic pancreatic cancer and 19,475 patients (13.9%) were identified with aspirin use and 120,177 patients (86.1%) with no aspirin use. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) (aOR) 0.531; p value <0.001 95% CI (confidence interval): 0.419 – 0.673. Patients with aspirin use also demonstrated significantly reduced odds of developing a pulmonary embolism, portal vein thrombosis, acute kidney injury, renal replacment therapy, septic shock, of requiring an ICU level of care. Conclusion The mortality increase in pancreatic cancer mortality, albeit alarming, serves as a driving force for treatment innovation with continual examination of current treatments and our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in pancreatic cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing non metastatic pancreatic cancer. Our findings support that aspirin exerts shielding effects against in-hospital mortality and protects patients with non metastatic pancreatic cancer from the development of major in hospital comorbidities as compared to those who do not use aspirin.

15 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
OOOmar Aaron Oudit
Omar Aaron Oudit
TATemitayo Adebowale
Temitayo Adebowale
AAAbdulrahman Atasi
Abdulrahman Atasi
KPKibwey Peterkin
Kibwey Peterkin
JPJamal Perry
Jamal Perry
JSJamil Shah
Jamil Shah
Introduction Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX dependent and independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methodology The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long term use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including rates of pulmonary embolism, portal vein thrombosis, acute kidney injury and need for renal replacement therapy, septic shock and rates of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 569,306 patients were identified with colorectal cancer and 11.7% (66,608) of this population were identified with long term use of aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.530, p value <0.001 95% CI (confidence interval): 0.460 – 0.617. Patients with aspirin use also demonstrated significantly reduced odds of gastrointestinal, hepatic, pulmonary and retroperitoneal/peritoneal metastasis; (aOR 0.606, 95% CI: 0.564-0.653, P<0.001), (aOR 0.628, 95% CI: 0.582 – 0.678, P<0.001), (aOR 0.676, 95% CI: 0.605 – 0.755, P<0.001) and (aOR 0.751, 95% CI: 0.685 – 0.825, P<0.001) respectively. Conclusion In recent years there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2 mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contribute to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. Aspirin use is also linked to a significant reduction in odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings reveal that aspirin exerts shielding effects against in-hospital mortality and protects patients with colorectal cancer from the development of major comorbid conditions and metastatic disease as compared to those who do not use aspirin.

12 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
OOOmar Aaron Oudit
Omar Aaron Oudit
TATemitayo Adebowale
Temitayo Adebowale
MLMatthew Levy
Matthew Levy
JJJaved Jagroo
Javed Jagroo
SNSharanya R. Nemakallu
Sharanya R. Nemakallu
DCDerrick Cheung
Derrick Cheung
The Warburg effect is a metabolic phenomenon observed in cancer cells and is characterized by aerobic glycolysis instead of mitochondrial oxidative phosphorylation as the primary mechanism of cellular energy generation. The exact benefit of such a metabolic switch is poorly understood, as aerobic glycolysis is thermodynamically more inefficient than mitochondrial oxidative phosphorylation. Here, we present a case of a 40-year-old male with advanced stage 4 hepatocellular carcinoma with chronically low glucose levels measured in the 20s to 40s and completely asymptomatic. Upon examination, findings of sympathetic hyperactivity in the setting of hypoglycemia were absent, and mentation was completely intact. This occurred in the absence of any states or medications known to induce hypoglycemia; concurrently, the patient demonstrated hyperphagia, suggesting increased metabolic demand in the setting of an immense, overwhelming tumor burden. During these hypoglycemic intervals, the patient's coagulation profile, including PT and international normalized ratio, remained within normal limits, suggesting sufficient residual hepatic parenchyma and glucogenic capacity. The patient's glucose remained extremely low, refractory to correction with multiple dextrose, D5, and D10 administrations. This suggests chronic systemic habituation to malignant cell consumption of serum glucose leading to adaptations to this hypoglycemia in highly metabolically active organs, such as the brain, heart, liver, and kidneys. This report highlights the clinical utility of recognizing this metabolic state in the setting of advanced-stage malignancy with significant tumor burden and how it affects hospital glucose management. Its early recognition will lead to improvements in meeting the patient's metabolic demands while avoiding paradoxical exacerbation of lactic acidosis when providing guideline-directed oncological treatment. This metabolic state may function as a surrogate marker, in conjunction with serum markers and imaging studies, for clinical identification of advanced stage malignancies and for treatment escalation.

Verified
Journal Article
Open access
PDF file
OOOmar Aaron Oudit
Omar Aaron Oudit
TATemitayo Adebowale
Temitayo Adebowale
AAAbdulrahman Atasi
Abdulrahman Atasi
KPKibwey Peterkin
Kibwey Peterkin
JPJamal Perry
Jamal Perry
JSJamil Shah
Jamil Shah
Background: Aspirin, initially recognized for its anti-inflammatory, antipyretic and analgesic properties, holds a prominent role in the treatment of cardiovascular disease. The utility of aspirin in cancer therapeutics has been explored and stratified into COX-dependent and -independent mechanisms. COX2 gene expression has been demonstrated to be significantly upregulated in colorectal cancer and various other gastrointestinal malignancies including pancreatic, esophageal, and gastric cancer. This study investigates the relationship of aspirin use and outcomes in patients with colorectal cancer. Methods: The Nationwide Inpatient Sample (NIS) database from 2017 to 2022 was analyzed for patients age > 18 who were hospitalized for colorectal cancer and its decompensations using ICD-10 diagnostic codes. These patients were further stratified based on the long-term use of aspirin. The principal outcome of this investigation are the odds of in-hospital mortality, with secondary outcomes including odds of pulmonary embolism, portal vein thrombosis, acute kidney injury, septic shock, requiring an ICU level of care and odds of hepatic, pulmonary, gastrointestinal and peritoneal or retroperitoneal metastatic disease. Multivariate logistic regression accounting for hospital and patient characteristics was implemented for analysis, with the Charlson Comorbidity Index used to adjust for coexisting comorbidity burden; a p-value (p) of <0.05 was considered statistically significant. Results: In our analysis of the NIS, 596,160 patients were identified with colorectal cancer and 11.7% (69,750) of this population were identified with long-term use of aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.530, p value < 0.001 95% CI (confidence interval): 0.460–0.617. Patients with aspirin use also demonstrated significantly reduced odds of adverse outcomes and gastrointestinal, hepatic, pulmonary and retroperitoneal/peritoneal metastasis; (aOR 0.606, 95% CI: 0.564–0.653, p < 0.001), (aOR 0.628, 95% CI: 0.582–0.678, p < 0.001), (aOR 0.676, 95% CI: 0.605–0.755, p < 0.001) and (aOR 0.751, 95% CI: 0.685–0.825, p < 0.001) respectively. Conclusions: In recent years, there has been an alarming increase in incidence of colorectal cancer, particularly amongst younger individuals with increased associated mortality. This mortality increase, albeit alarming, is a driving force for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. COX2-mediated signaling serves as a key promotor of tumorigenic molecular signaling that directly contributes to tumor cell proliferation, angiogenesis and metastasis in colorectal cancer. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced odds of in-hospital mortality. Aspirin use is also associated with significantly reduced odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings convey that aspirin use reduces the likelihood of in-hospital mortality, major comorbid conditions and of developing metastatic disease as compared to those who do not use aspirin.

8 September 2026 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
OOOmar Aaron Oudit
Omar Aaron Oudit
TATemitayo Adebowale
Temitayo Adebowale
MLMatthew Levy
Matthew Levy
JJJaved Jagroo
Javed Jagroo
SNSharanya R. Nemakallu
Sharanya R. Nemakallu
DCDerrick Cheung
Derrick Cheung
Background: The Warburg effect is a metabolic phenomenon observed in cancer cells that is characterized by aerobic glycolysis instead of mitochondrial oxidative phosphorylation as the primary mechanism of cellular energy generation. The exact benefit of such a metabolic switch is poorly understood, as aerobic glycolysis is thermodynamically more inefficient than mitochondrial oxidative phosphorylation. Case Presentation: Here, we present a case of a middle-aged individual with advanced stage 4 hepatocellular carcinoma with chronically low glucose levels measured in the 20 s to 40 s and completely asymptomatic. Upon examination, findings of sympathetic hyperactivity in the setting of hypoglycemia were absent, and mentation was completely intact. This occurred in the absence of any states or medications known to induce hypoglycemia; concurrently, the patient demonstrated hyperphagia, suggesting increased metabolic demand in the setting of an immense, overwhelming tumor burden. During these hypoglycemic intervals, the patient’s coagulation profile, including PT and international normalized ratio, remained within normal limits, suggesting sufficient residual hepatic parenchyma and glucogenic capacity. The patient’s glucose remained extremely low, refractory to correction with multiple dextrose, D5, and D10 administrations. This suggests chronic systemic habituation to malignant cell consumption of serum glucose leading to adaptations to this hypoglycemia in highly metabolically active organs, such as the brain, heart, liver, and kidneys. Discussion and Conclusions: This report highlights the clinical utility of recognizing this metabolic state in the setting of advanced-stage malignancy with significant tumor burden and how it affects hospital glucose management. Its early recognition will lead to improvements in meeting the patient’s metabolic demands while avoiding paradoxical exacerbation of lactic acidosis when providing guideline-directed oncological treatment. This metabolic state holds the potential to function as a surrogate marker, in conjunction with serum markers and imaging studies, for clinical identification of otherwise clinically silent advanced stage malignancies and for treatment escalation.

15 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
OOOmar Aaron Oudit
Omar Aaron Oudit
TATemitayo Adebowale
Temitayo Adebowale
LTLuka Tinikashvili
Luka Tinikashvili
EOEfe A. Okunzuwa
Efe A. Okunzuwa
MTMuhammad S. Tahir
Muhammad S. Tahir
JSJamil Shah
Jamil Shah
Introduction Aspirin initially recognized for its anti-inflammatory, antipyretic and analgesic properties hold a prominent role in the treatment of cardiovascular disease. Cyclooxygenase, COX, 1 and 2 activity in cirrhotic liver disease has been studied by several groups and stratified into COX dependent and independent mechanisms. COX2 gene expression has been identified to be significantly increased in cirrhotic liver disease and various other states of chronic hepatic inflammation. Our study investigates the relationship of aspirin use, an established COX inhibitor, and outcomes in patients hospitalized with ascitic cirrhosis. Methodology The National Inpatient Sample, NIS, database from 2017 to 2022 was analyzed for patients age >18 who were hospitalized for ascitic cirrhosis and its decompensations using ICD-10 diagnostic codes. These patients were further partitioned based on their use of aspirin. The principal outcome of this investigation is in-hospital mortality, with secondary outcomes including odds of portal vein thrombosis, septic shock, ICU admission and acute kidney injury. Secondary outcomes also included the odds of developing hepatic decompensations including need for EGD, hepatorenal syndrome, spontaneous bacterial peritonitis, SBP, developing HCC with and without pulmonary metastasis and of undergoing a transjugular intrahepatic portosystemic shunt, TIPS, procedure. Multivariate logistic regression was applied to the outcomes, and the Charlson Comorbidity Index was used to adjust for confounders. A p-value (pv) of <0.05 was considered statistically significant. Results In our analysis of the NIS, 568,990 patients were identified with ascitic cirrhosis and 11.7% (66,572) of this population were identified to use aspirin. Aspirin use was identified to have a significantly reduced odds of in-patient mortality (adjusted odds ratio) [aOR] 0.540, p value <0.001 95% CI (confidence interval): 0.461 – 0.631. Patients with aspirin use demonstrated significantly reduced odds of portal vein thrombosis, septic shock, ICU admission, and acute kidney injury. Those with ascitic cirrhosis and aspirin use also conveyed reduced odds of developing hepatocellular carcinoma, pulmonary metastasis and hepatic decompensations including hepatorenal syndrome and of undergoing TIPS. Discussion Cirrhotic liver disease remains a global health burden with increasing prevalence and mortality in recent years. This mortality increase remains a critical driver for treatment innovation with continual examination of our repertoire of medications for possible repurposed applications. Elevated COX2 expression has been identified to mediate and accelerate acute and chronic inflammatory states therefore driving the onset of cirrhotic liver disease and hepatic decompensation. Aspirin use and its inhibitory action on COX2 demonstrated a significantly reduced risk of in-hospital mortality. These findings reveal that aspirin use is also linked to a significant reduction in odds of in-hospital mortality, of developing major secondary complications and of developing hepatic decompensation known to increase mortality and morbidity in those with cirrhosis as compared to those who do not use aspirin.